Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Nyhet

Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”

Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”

Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of next-generation radioconjugates to treat cancer.

The deal showcases rising interest in the field of radiopharmaceuticals.

Lorem ipsum dolor sit amet. Est omnis iusto eos velit nostrum et pariatur quod non. Consequuntur nemo id dolores tempora ut quis quis eum. Porro dolore rem voluptas iste. Consequuntur nemo id dolores tempora ut quis quis eum

Denna källa har få eller inga artiklar bakom betalvägg
Läs hela artikeln hos Biostock

Nyhetsbrev